Evotec SE (EVO) stock
EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 8, 2026Score 4/30
$1.46−0.02 (-1.35%)
Close on Nov 18, 2026Market cap $519.11MP/E –Yield –
Evotec revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was €788.37M, down 1.1% from the year before. The highest annual figure on record is €796.97M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €788.37M | -1.1% |
| FY2024 | Dec 31, 2024 | €796.97M | +2.0% |
| FY2023 | Dec 31, 2023 | €781.43M | +4.0% |
| FY2022 | Dec 31, 2022 | €751.45M | +21.6% |
| FY2021 | Dec 31, 2021 | €618.03M | +23.4% |
| FY2020 | Dec 31, 2020 | €500.92M | +12.2% |
| FY2019 | Dec 31, 2019 | €446.44M | – |
See a number that looks wrong?